Evidence map›Paper›PMID 31450932›Full record

ArticleAsian Pacific journal of cancer prevention : APJCP2019

Preliminary In Vitro Effects of CD8+ T Lymphocyte Specific for the CD20 Alternative Splicing D393-CD20 Peptide Expressed on Burkitt Lymphoma Cells.

Hamid Chegni, Zuhair M Hassan, Roberto Nisini, Marzieh Ebrahimi, Farzaneh Sabouni

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Asian Pacific journal of cancer prevention : APJCP, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Hamid ChegniDepartment of Immunology, School of Medical Sciences, Tarbiat Modares University, Tehran, Iran. Email: hasan_zm@modares.ac.ir
Zuhair M HassanDepartment of Immunology, School of Medical Sciences, Tarbiat Modares University, Tehran, Iran. Email: hasan_zm@modares.ac.ir
Roberto NisiniDepartment of Infectious, Parasitic and Immune-Mediated Diseases, National Institute of Health, Viale Regina Elena 299, 00161 Rome, Italy.
Marzieh EbrahimiDepartment of Stem Cells and Developmental Biology, Cell Science Research Centre, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran.
Farzaneh SabouniNational Institute of Genetic Engineering and Biotechnology, Tehran, Iran.
Tarbiat Modares University · IRAcademic Center for Education, Culture and Research · IRNational Institute of Genetic Engineering and Biotechnology · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The effective discovery of clinically relevant tumor antigens holds a fundamental role for the development of new diagnostic tools and anticancer immunotherapies. D393-CD20 mRNA is absent from normal resting B cells but present in various malignant or transformed B cells. CD8+T lymphocytes play a central role in immunity to cancer. In this study, we want use from T CD8+ against D393-CD20 for effect in RAMOS cell line. After isolation and expanding of specific TCD8 + Lymphocyte against D393-CD20 antigen, for examining the effect of specialized T lymphocyte clone of D393-CD20 antigen on RAMOS cell line, we co-cultured them together, and the rate of apoptosis were examined by flow cytometry and cytotoxicity techniques by using MTT technique. We observed that specialized TCD8+ lymphocyte of D393-CD20 antigen can induce apoptosis in malignant B-lymphocytes, and this antigen can be a proper target for immunotherapy.

Indexed as

Alternative SplicingAntigens, CD20Antigens, NeoplasmBurkitt LymphomaCD8-Positive T-LymphocytesCell ProliferationHumansIn Vitro TechniquesPeptide FragmentsTumor Cells, CulturedAntigens, CD20Antigens, NeoplasmPeptide Fragmentsalternative splicingBurkitt lymphomaCD8+ T LymphocyteD393-CD20 peptide

Identifiers

PMID31450932
PMCPMC6852797
OpenAlexW2969326257

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.